Dr. Steven E. Finkelstein spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Friday, November 14, 2014 on “Advancing Patient Access to Novel Care: Radiation Driven Immunotherapy.”
Keywords: radiation driven immunotherapy, prostate cancer
How to cite: Finkelstein, Steven E. “Advancing Patient Access to Novel Care: Radiation Driven Immunotherapy” Grand Rounds in Urology. August 3, 2015. Accessed Apr 2024. https://grandroundsinurology.com/advancing-patient-access-novel-care.
References
Agassi AM, Myslicki FA, Shulman JM, et al. The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. Future Oncol. 2014 Dec;10(15):2319-28.
http://www.ncbi.nlm.nih.gov/pubmed/25525842
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014 Jan;11(1):24-37.
http://www.ncbi.nlm.nih.gov/pubmed/24247168
Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011;2011:439752.
http://www.ncbi.nlm.nih.gov/pubmed/22162711
Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012 Nov 26;2:169.
http://www.ncbi.nlm.nih.gov/pubmed/23233905
Mitchell CR, Lowe VJ, Rangel LJ, et al. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography forprostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr;189(4):1308-13.
http://www.ncbi.nlm.nih.gov/pubmed/23123372
